Table 1. Patient characteristics of Hodgkin lymphoma patients.
| Control (no bleomycin) | All bleomycin treated patients | p-value* | Only ABVD treated patients | p-value** | |
|---|---|---|---|---|---|
| Number of patients | 29 | 102 | 68 | ||
| Bleomycin dose, mg/m2 (median, range) | 0 | 130 (40–160) | N/A | 120 (60–160) | N/A |
| N/A | |||||
| Age, years (median, range) | 28 (14–57) | 30 (14–73) | 0.871 | 30 (15–62) | 0.143 |
| Male/female | 16/13 | 55/47 | 0.764 | 40/28 | 0.740 |
| Years since treatment (median, range) | 28 (15–44) | 10 (2–25) | <0.0001 | 8 (2–22) | <0.0001 |
| Number of patients (%) | |||||
| Stage | |||||
| early | 16 (55.17) | 52 (51.00) | 0.361 | 43 (63.24) | 0.880 |
| advanced | 13 (44.83) | 50 (49.00) | 25 (36.76) | ||
| Histology | |||||
| NPLHL | 2 (6.90) | 3 (2.94) | 0.318 | 3 (4.41) | 0.575 |
| cHL | 27 (93.10) | 99 (97.06) | 65 (95.59) | ||
| BLMH genotype | |||||
| G/G | 5 (17.24) | 10 (9.80) | 6 (8.82) | ||
| A/G | 10 (34.48) | 34 (33.33) | 0.296 | 22 (32.35) | 0.253 |
| A/A | 14 (48.28) | 58 (58.86) | 40 (58.82) | ||
| Smokers | 5 (17.24) | 29 (28.43) | 0.645 | 22 (32.35) | 0.673 |
| Chest irradiation | 13 (44.83) | 49 (48.04) | 0.727 | 31 (45.49) | 0.945 |
| Use of G-CSF | N/A | 18 (17.65) | N/A | 13 (19.12) | N/A |
| Creatinine clearance, μmol/min (median, range) | N/A | 72 (47–99) | N/A | 69 (45–98) | N/A |
* Comparison of "All bleomycin treated patients" and "Controll group"
** Comparison of "Only ABVD treated patients" and "Controll group
A total of 131 patients were treated with either bleomycin-containing therapy (ABVD, BEACOPP, COPP/ABV, relapsed/ refractory patients) (n = 102) or excluding bleomycin, regarded as a control group (irradiation only, COPP, CVPP) (n = 29). Within the bleomycin-treated cohort a total number of 68 patients were treated with ABVD regimen alone. p values are considered significant if <0.05 and are marked bold. N/A—not applicable, ABVD—adriamycin (doxorubicin), bleomycin, vinblastin, dacarbazine, BEACOPP—bleomycin, etoposide, adriamycin (doxorubicin), cyclophosphamide, oncovin (vincristine), procarbazine, prednisone), COPP/ABV—cyclophophamide, vincristin, prednisone, procarbazine doxorubicin, bleomycin, vinblastin, COPP—cyclophophamide, vincristin, prednisone, procarbazine, CVPP—cyclophophamide, vinblastine, prednisone, procarbazine, NLPHL—nodular lmyphocyte predominat Hodgkin lymphoma, cLR—classical lymphocyte rich, cMC—classical mixed cellularity, cNS—classical nodular sclerosis, cLD—classical lymphocyte depletion, ND—not determined, G-CSF—granulocyte colony stimulating factor.